![Christopher Haqq](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Haqq
Chief Tech/Sci/R&D Officer at
ELICIO THERAPEUTICS, INC.
Net worth: 89 547 $ as of 2026-07-30
Profile
Christopher M.
Haqq currently works at Elicio Therapeutics, Inc., as Chief Medical Officer & Executive Vice President from 2019.
Dr. Haqq also formerly worked at Consonance-HFW Acquisition Corp., as Independent Director from 2020 to 2021, Amgen, Inc., as Manager-Early Development Oncology Group, Cougar Biotechnology, Inc., as Vice President-Clinical Research & Development from 2007 to 2009, The University of California, San Francisco, as Assistant Professor, Janssen Oncology, Inc., as Vice President-Clinical Research & Development from 2007 to 2011, Atara Biotherapeutics, Inc., as Chief Scientific Officer, Executive VP-R&D from 2012 to 2019, and Elicio Therapeutics, Inc. (United States), as Chief Medical Officer & Executive Vice President from 2019 to 2023.
Dr. Haqq received his undergraduate degree from Stanford University and doctorate degree from Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-07-15 | 31,981 ( 0.14% ) | 89 547 $ | 2026-07-30 |
Christopher Haqq active positions
| Companies | Position | Start |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-09-30 |
Former positions of Christopher Haqq
| Companies | Position | End |
|---|---|---|
Elicio Therapeutics, Inc. (United States)
 Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Chief Tech/Sci/R&D Officer | 2023-05-31 |
| SURROZEN, INC. | Director/Board Member | 2021-03-31 |
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-10-24 |
Janssen Oncology, Inc.
 Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Chief Tech/Sci/R&D Officer | 2011-08-31 |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Chief Tech/Sci/R&D Officer | 2009-07-12 |
Training of Christopher Haqq
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
57
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Consonance-HFW Acquisition Corp.
 Consonance-HFW Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Elicio Therapeutics, Inc.
 Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
- Stock Market
- Insiders
- Christopher Haqq
